Palliative radiotherapy regimens for non-small cell lung cancer (Q24243920)

Adaptive radiation therapy

Europe PubMed Central

title

Palliative radiotherapy regimens for non-small cell lung cancer (English)

0 references

main subject

0 references

non-small-cell lung carcinoma

1 reference

Jason F Lester

1

J F

Lester

1 reference

30 October 2023

Fergus Macbeth

series ordinal

2

author given names

F R

author last names

Macbeth

1 reference

30 October 2023

Elizabeth Toy

series ordinal

3

author given names

E

author last names

Toy

1 reference

30 October 2023

Bernadette Coles

series ordinal

4

author given names

B

author last names

Coles

1 reference

Cochrane Database of Systematic Reviews

30 October 2023

publication date

18 October 2006

0 references

published in

0 references

cites work

Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Palliative radiotherapy for lung cancer: two versus five fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Hypofractionated irradiation for inoperable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Immediate side effects of large fraction radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Audit: the use of radiotherapy for NSCLC in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Measuring quality of life in oncology: is it worthwhile? II. Experiences from the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Invited review: permanent radiation myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Loss of local control with prolongation in radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

A case of radiation myelopathy after 2 x 8.5 Gy for inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Acute changes in peak expiratory flow rate following palliative radiotherapy for bronchial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

The use of discriminant analysis to guide palliative treatment for lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

[Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Wor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002143.PUB2

7 January 2021

10.1002/14651858.CD002143.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_r3qodakafjfi7i7eyo3s2gfp6i

0 references